Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH)

• Status: Unknown status
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

1. To assess the metabolic factors in lean and obese patients with NASH.

2. To compare the efficacy of pentoxifylline versus pioglitazone on the metabolic profile and liver histology of NASH patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Govind Ballabh Pant Hospital
• Treatments: Pentoxifylline; Pioglitazone

Criteria

Inclusion Criteria:

• Patients with biopsy proven NASH will be enrolled. Abdominal USG showing diffusely echogenic liver suggestive of fatty infiltration of liver.

• ALT > 1.2 times the upper limit of normal for > 6 months.(atleast three readings one month apart)

• Liver Biopsy showing steatosis affecting >10% of hepatocytes with necroinflammatory activity, ballooning hepatocytes &/ or fibrosis.

Exclusion Criteria:

• Alcohol intake of more than 20g/wk

• Evidence of viral/ autoimmune hepatitis

• PBC (Primary biliary cirrhosis)

• Biliary obstrution

• Wilson disease

• Haemchromatosis

• Decompensated cirrhosis

• Drug ingestion of the follwing drugs for a period of more than 4 weeks during past 6 weeks - Amiodarone, Methotrexate, Perhexiline, Glucocorticoids, Estrogens, Tamoxifen, Nifedipine, Diltiazem, Tamoxifen.

• DM Type I